Fosun Pharma is implementing its 4IN strategy—Innovation, Internationalization, Intelligentization, and Integration—with core operations spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. The company has developed international R&D teams across China, the United States, and India, establishing platforms for innovative chemical drugs, biologics, high-value generic drugs, and cell therapy.
Cyborg Score Rationale
Fosun Pharma generated $5.8B in revenue (2024) with a net profit margin of 20.0% and market cap of $7.9B. The company maintains strong profitability and a diversified business portfolio spanning pharmaceuticals, healthcare services, and medical devices, though it faces intense competition in China's pharmaceutical sector.
Top Insights
Recent pipeline advancement: (March 2026) approved clinical trials for LBP-ShC4; (March 2026) approved clinical trials for FXB0871 in solid tumors; (May 2026) partnered with AriBio on AR1001, an innovative Alzheimer's drug with global exclusive option rights.
Healthcare services expansion includes United Family Hospital maintaining premium healthcare leadership in Beijing, Tianjin, Shanghai, and other major metropolitan areas.
Diversified product offerings include vaccines, medical devices, COVID-19 vaccines, and mRNA vaccines alongside core pharmaceutical products.
Business composition: pharmaceutical R&D and manufacturing represent 72.1% of net sales, medical devices and diagnostics 17.3%, and medical/hospital services 10.5%.
Named Competitors
Innovative Pharmaceuticals & Services — Chinese biopharmaceutical company focused on plasma-derived products
Pharmaceutical Manufacturing — Major state-owned pharmaceutical distributor and retail network partner
Integrated Healthcare — Chinese pharmaceutical company with medical device operations
Recent Developments
(March 2026) Clinical trial approval for LBP-ShC4 from NMPA
(March 2026) Clinical trial approval for FXB0871 in treatment of locally advanced or metastatic solid tumors
(May 2026) Global exclusive option agreement with AriBio for AR1001 Alzheimer's disease treatment
Open the full interactive Shanghai Fosun Pharmaceutical (Group) Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.